Seshadri S, Wolf PA. Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study. Lancet Neurol. 2007;6(12):1106–14.

Article  PubMed  Google Scholar 

Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging. 2006;27(10):1372–84.

Article  CAS  PubMed  Google Scholar 

Counts SE, Alldred MJ, Che S, Ginsberg SD, Mufson EJ. Synaptic gene dysregulation within hippocampal CA1 pyramidal neurons in mild cognitive impairment. Neuropharmacology. 2014;79:172–9.

Article  CAS  PubMed  Google Scholar 

Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer's disease. Lancet. 2021;397(10284):1577–90.

Tzioras M, McGeachan RI, Durrant CS, Spires-Jones TL. Synaptic degeneration in Alzheimer disease. Nat Rev Neurol. 2023;19(1):19–38.

Article  PubMed  Google Scholar 

Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement. 2024;20(8):5143–69.

Article  PubMed  PubMed Central  Google Scholar 

Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572–80.

Article  CAS  PubMed  Google Scholar 

DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann Neurol. 1990;27(5):457–64.

Article  CAS  PubMed  Google Scholar 

Blennow K, Bogdanovic N, Alafuzoff I, Ekman R, Davidsson P. Synaptic pathology in Alzheimer’s disease: Relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transm. 1996;103(5):603–18.

Article  CAS  PubMed  Google Scholar 

Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer’s disease: implications for prevention trials. Neuron. 2014;84(3):608–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease. EMBO Mol Med. 2019;11(12): e11170.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Galvin JE, Uryu K, Lee VMY, Trojanowski JQ. Axon pathology in Parkinson’s disease and Lewy body dementia hippocampus contains α-, β-, and γ-synuclein. Proc Natl Acad Sci. 1999;96(23):13450–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mori F, Tanji K, Yoshimoto M, Takahashi H, Wakabayashi K. Immunohistochemical comparison of alpha- and beta-synuclein in adult rat central nervous system. Brain Res. 2002;941(1–2):118–26.

Article  CAS  PubMed  Google Scholar 

Oeckl P, Metzger F, Nagl M, von Arnim CA, Halbgebauer S, Steinacker P, et al. Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer’s and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies. Mol Cell Proteomics. 2016;15(10):3126–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oeckl P, Halbgebauer S, Anderl-Straub S, von Arnim CAF, Diehl-Schmid J, Froelich L, et al. Targeted mass spectrometry suggests beta-synuclein as synaptic blood marker in Alzheimer’s disease. J Proteome Res. 2020;19(3):1310–8.

Article  CAS  PubMed  Google Scholar 

Halbgebauer S, Oeckl P, Steinacker P, Yilmazer-Hanke D, Anderl-Straub S, von Arnim C, et al. Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2021;92(4):349–56.

Article  PubMed  Google Scholar 

Oeckl P, Wagemann O, Halbgebauer S, Anderl-Straub S, Nuebling G, Prix C, et al. Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181. Ann Neurol. 2022;92(1):6–10.

Article  CAS  PubMed  Google Scholar 

Barba L, Abu Rumeileh S, Bellomo G, Paolini Paoletti F, Halbgebauer S, Oeckl P, et al. Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2023;94(1):83–6.

Article  PubMed  Google Scholar 

Oeckl P, Anderl-Straub S, Danek A, Diehl-Schmid J, Fassbender K, Fliessbach K, et al. Relationship of serum beta-synuclein with blood biomarkers and brain atrophy. Alzheimers Dement. 2023;19(4):1358–71.

Article  CAS  PubMed  Google Scholar 

Oeckl P, Bluma M, Bucci M, Halbgebauer S, Chiotis K, Sandebring-Matton A, et al. Blood β-synuclein is related to amyloid PET positivity in memory clinic patients. Alzheimers Dement. 2023;19(11):4896–907.

Article  CAS  PubMed  Google Scholar 

Hayashi J, Carver JA. β-Synuclein: an enigmatic protein with diverse functionality. Biomolecules. 2022;12(1):142.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pilotto A, Bongianni M, Tirloni C, Galli A, Padovani A, Zanusso G. CSF alpha-synuclein aggregates by seed amplification and clinical presentation of AD. Alzheimers Dement. 2023;19(8):3754–9.

Article  CAS  PubMed  Google Scholar 

Bellomo G, Toja A, Paolini Paoletti F, Ma Y, Farris CM, Gaetani L, et al. Investigating alpha-synuclein co-pathology in Alzheimer’s disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay. Alzheimers Dement. 2024;20(4):2444–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van der Flier WM, Pijnenburg YA, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis. 2014;41(1):313–27.

Article  PubMed  Google Scholar 

van der Flier WM, Scheltens P. Amsterdam Dementia Cohort: Performing Research to Optimize Care. J Alzheimers Dis. 2018;62(3):1091–111.

Article  PubMed  PubMed Central  Google Scholar 

Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10(6):844–52.

Article  PubMed  Google Scholar 

Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–9.

Article  PubMed  Google Scholar 

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.

Article  PubMed  Google Scholar 

Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183–94.

Article  CAS  PubMed  Google Scholar 

Willemse EAJ, Tijms BM, van Berckel BNM, Le Bastard N, van der Flier WM, Scheltens P, Teunissen CE. Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2021;13(1):e12182.

Willemse EAJ, van Maurik IS, Tijms BM, Bouwman FH, Franke A, Hubeek I, et al. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer’s disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. Alzheimers Dement (Amst). 2018;10:563–72.

Article  PubMed  Google Scholar 

Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73(22):1914–22.

Article  CAS